Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;8(1):8-14.
doi: 10.4103/0976-0105.195080.

Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile

Hayder M Al-Kuraishy  1 , Ali I Al-Gareeb  1
Affiliations

Effects of Rosuvastatin Alone or in Combination with Omega-3 Fatty Acid on Adiponectin Levels and Cardiometabolic Profile

Hayder M Al-Kuraishy et al. J Basic Clin Pharm. 2016 Dec.

Abstract

Background: Adiponectin is an important adipocyte-related protein that has been postulated to participate in prevention of the development of metabolic syndrome. The relationship between adiponectin serum levels and risk of coronary artery disease (CAD) has been widely investigated and remains controversial. The aim of the present study was to evaluate the effects of rosuvastatin and/or omega-3 fatty acid on adiponectin serum levels in patients with insulin resistance (IR) and CAD.

Patients and methods: This study involved 87 patients with CADs and IR of different etiology, the patients were divided into three groups; 24 patients on treatment with rosuvastatin, 22 patients on treatment with omega-3 fatty acid, 23 patients on treatment with omega-3 fatty acid and rosuvastatin, 18 patients were not previously or currently treated with either rosuvastatin or omega-3 fatty acid, those regarded as control patients. Anthropometric measures, adiponectin serum levels, and other biochemical parameters were assessed in each treated group.

Results: Rosuvastatin therapy leads to a significant elevation in adiponectin serum levels from 4.1 ± 0.99 ng/mL to 6.76 ± 1.03 ng/mL compared to control P < 0.01. Omega-3 fatty acid therapy leads to a significant elevation in adiponectin serum levels from 4.1 ± 0.99 ng/mL to 6.11 ± 1.29 ng/mL compared to control P < 0.01. Rosuvastatin plus omega-3 fatty acid therapy lead to a significant elevation in adiponectin serum levels from 4.1 ± 0.99 ng/mL to 7.99 ± 1.76 ng/mL compared to control P < 0.01.

Conclusions: Rosuvastatin and/or omega-3 fatty acid lead to significant cardiometabolic protection through an increment in adiponectin serum levels.

Keywords: Adiponectin; omega-3 fatty acid; rosuvastatin.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Effects of rosuvastatin and/or O-3FA on adiponectin serum levels in coronary heart disease compared to control. O-3FA: Omega-3 fatty acid; O-3FA + R: Omega-3 fatty acid plus rosuvastatin
See this image and copyright information in PMC

References

    1. Wal P, Wal A, Nair VR, Rai AK, Pandey U. Management of coronary artery disease in a tertiary care hospital. J Basic Clin Pharm. 2013;4:31–5. - PMC - PubMed
    1. Shams M, Rasekhi Kazerouni A, Ostovan MA, Omrani GR. The relationship between serum adiponectin levels with the presence and severity of coronary artery disease. Arch Iran Med. 2012;15:611–6. - PubMed
    1. Ikeda Y, Hama S, Kajimoto K, Okuno T, Tsuchiya H, Kogure K. Quantitative comparison of adipocytokine gene expression during adipocyte maturation in non-obese and obese rats. Biol Pharm Bull. 2011;34:865–70. - PubMed
    1. Coppola A, Marfella R, Coppola L, Tagliamonte E, Fontana D, Liguori E, et al. Effect of weight loss on coronary circulation and adiponectin levels in obese women. Int J Cardiol. 2009;134:414–6. - PubMed
    1. Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab. 2007;9:282–9. - PubMed

LinkOut - more resources